Article in Exploration of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Yixuan WangBiomedical Genetics, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Jinghan HuangBiomedical Genetics, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0003-0628-6022
Ting Fang Alvin AngDepartment of Anatomy & Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0003-4687-2552
Yibo ZhuBiomedical Genetics, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-5160-6764
Qiushan TaoDepartment of Pharmacology, Physiology and Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Jesse MezAlzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0003-1438-5442
Michael AloscoAlzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Gerald V DenisHematology & Medical Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-9886-0401
Anna BelkinaDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-7967-6254
Ashita GurnaniDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Mark RossSchool of Energy, Geosciences, Infrastructure and Society, Institute of Life and Earth Sciences, Heriot-Watt University, EH14 4AS Edinburgh, UK.
Bin GongDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Jingyan HanVascular Biology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-9893-2575
Kathryn L LunettaDepartments of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA.ORCID 0000-0002-9268-810X
Thor D SteinAlzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-6954-4477
Rhoda AuDepartment of Anatomy & Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-7742-4491
Lindsay A FarrerBiomedical Genetics, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-5533-4225
Xiaoling ZhangBiomedical Genetics, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-8237-1857
Wei Qiao QiuAlzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Funding
TBDU19AG068753 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au · 2020 to 2026
$42.4M
Alzheimer Disease Genetic Architecture in African AmericansR01AG048927 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Lindsay A. Farrer · 2015 to 2026
$8.4M
Multi-center development of a novel diagnostic test for Alzheimer's diseaseR01AG059424 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARLOW, MARTIN RHYS, KOWALL, NEIL W. · 2018 to 2022
$6.4M
Identification and characterization of the CD31-ApoE-mCRP pathway for Alzheimer's disease in humans.RF1AG075832 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI EMILI, ANDREW, QIU, WEI QIAO WENDY · 2023 to 2023
$2.4M
Genomic and Biological Studies of APOE ε2 in Alzheimer DiseaseRF1AG057519 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARRER, LINDSAY A., JUN, GYUNGAH · 2017 to 2017
$2.4M
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
Aim: Endothelial dysfunction has been associated with both cerebrovascular pathology and Alzheimer's disease (AD). However, the connection between circulating endothelial cells and the risk of AD remains uncertain. The objective was to leverage data from the Framingham Heart Study to investigate various circulating endothelial subtypes and their potential correlations with the risk of AD. Methods: The study conducted data analyses using Cox proportional hazard regression and linear regression methods. Additionally, genome-wide association study (GWAS) was carried out to further explore the data. Results: Among the eleven distinct circulating endothelial subtypes, only circulating endothelial progenitor cells (EPCs) expressing CD34+CD133+ were found to be negatively and dose-dependently associated with reduced AD risk. This association persisted even after adjusting for age, sex, years of education, apolipoprotein E ( Conclusions: The findings suggest that circulating CD34+CD133+ EPCs possess a protective effect and may offer a new therapeutic avenue for AD, especially in individuals with vascular pathology and those carrying specific genotypes of
Indexed as
Alzheimer’s diseaseCD34+CD133+circulating endothelial progenitor cellsgenome-wide association studies (GWAS)vascular diseases
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The association between circulating CD34+CD133+ endothelial progenitor cells and reduced risk of Alzheimer's disease in the Framingham Heart Study. · full record | OpenQuestion